Clinic Roundup

 BioAlliance Pharma SA, of Paris, said the FDA approved a U.S. extension of its Phase II trial of Validive (clonidine Lauriad) for the prevention of radio/chemotherapy-induced oral mucositis in patients with head and neck cancer.